Overview

  • Product nameNatural Human C3c protein
  • Protein lengthFull length protein

Description

  • NatureNatural
  • SourceNative
  • Amino Acid Sequence
    • AccessionP01024
    • SpeciesHuman

Specifications

Our Abpromise guarantee covers the use of ab96038 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activityab96038 contains the intact Beta chain and the Alpha chain without the C3dg, C3a and C3f peptides. This material is suitable for raising polyclonal antiserum to C3.
  • Applications

    SDS-PAGE

  • Purity 99 % .
    ab96038 is >99% pure by SDS Page. We do not carry out mass spectrometry analysis to confirm this since we sell our C3 on the basis of their immunological activity.
  • FormLiquid
  • Additional notesStarting material donor tested and found negative for HIV I and II antibodies, Hepatitis B surface antigen, and Hepatitis C antibodies.ab96038 contains the intact Beta chain and the Alpha chain without the C3dg, C3a and C3f peptides. This material is suitable for raising polyclonal antiserum to C3.
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 0.15M Sodium chloride, 0.05M Monobasic dihydrogen sodium phosphate, pH 7.2

General Info

  • Alternative names
    • acylation-stimulating protein cleavage product
    • AHUS5
    • ARMD9
    • ASP
    • C3
    • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1
    • C3a
    • C3a anaphylatoxin
    • C3b
    • CO3_HUMAN
    • Complement C3
    • Complement C3c
    • Complement C3c alpha' chain fragment 2
    • Complement component 3
    • Complement component C3
    • Complement component C3a
    • Complement component C3b
    • Complement factor 3
    • CPAMD1
    • Prepro C3
    see all
  • FunctionC3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
    Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
  • Tissue specificityPlasma.
  • Involvement in diseaseDefects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
    Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
    Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • Sequence similaritiesContains 1 anaphylatoxin-like domain.
    Contains 1 NTR domain.
  • Post-translational
    modifications
    C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted.
  • Information by UniProt

References for Natural Human C3c protein (ab96038)

ab96038 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab96038.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"